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Background: CCR5 is a chemokine receptor 
and a co-receptor for HIV entry. 
Results: A pool of spare CCR5 binds the 
potent anti-HIV chemokine analog PSC-RANTES, 
but not native chemokines.  
Conclusion: Targeting a large number of 
CCR5 improves the anti-HIV property of PSC-
RANTES.  
Significance: Spare receptors represent a target 
for inhibiting HIV and might constitute a viral 
escape route. 
 
CCR5 binds the chemokines CCL3, CCL4, 
CCL5 and is the major co-receptor for HIV-1 
entry into target cells. Chemokines are 
supposed to form a natural barrier against 
HIV-1 infection. However, we showed that their 
antiviral activity is limited by CCR5 adopting 
low-chemokine affinity conformations at the 
cell surface. Here, we investigated whether a 
pool of CCR5 that is not stabilized by 
chemokines could represent a target for 
inhibiting HIV infection. We exploited the 
characteristics of the chemokine analog PSC-
RANTES, which displays potent anti-HIV-1 
activity. We show that native chemokines fail to 
prevent (i) high-affinity binding of PSC-
RANTES, (ii) the analog-mediated calcium 
release (in desensitization assays) and (iii) the 
analog-mediated CCR5 internalization. These 
results indicate that a pool of spare CCR5 may 
bind PSC-RANTES but not native chemokines. 
Improved recognition of CCR5 by PSC-
RANTES may explain why the analog promotes 
higher amounts of !-arrestin2/CCR5 
complexes, thereby increasing CCR5 down-
regulation and HIV-1 inhibition. Together these 
results highlight that spare CCR5, which might 
permit HIV-1 to escape from chemokines, 
should be targeted for efficient viral blockade. 
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The CC chemokine receptor 5 (CCR5) is a G 
protein-coupled receptor (GPCR) for the 
chemokines RANTES/CCL5, MIP1!/CCL3 and 
MIP1"/CCL4 (1). CCR5 is also a CD4-associated 
co-receptor required for human immunodeficiency 
virus type 1 (HIV-1) entry into host cells (2). It 
plays a prominent role during transmission, 
progression of infection and evolution to AIDS. 
Individuals that do not express a functional CCR5 
are highly resistant to HIV-1 infection without 
major pathological consequences (3). CCR5 is 
therefore a suitable therapeutic target for HIV-1 
blockade. A number of non-competitive and 
allosteric antagonists have been developed, among 
which Maraviroc is the only one currently used in 
HIV treatment (4). However, viral resistance to 
this drug is a major drawback highlighting the 
need for new inhibitors (5). 
GPCRs can oscillate between various inactive 
and active conformations at the cell surface (6). 
Structurally different ligands can stabilize and/or 
create distinct conformations (7) that interact with 
specific effectors including heterotrimeric G-
proteins and "-arrestins, which are scaffolding 
proteins involved in receptor desensitization and 
endocytosis (8). Reciprocally, interaction of a 
particular receptor conformation with an effector 
can increase the affinity of the receptor for the 
ligand (6). CCR5 exists in multiple conformations 
displaying distinct pharmacological and antigenic 
properties (9,10). This conformational 
heterogeneity is exploited by HIV-1 to escape 
inhibition by native CCR5-binding chemokines 
and small-molecule CCR5 inhibitors (10-12). 
Therefore, taking into account the multiplicity of 
CCR5 conformations is essential for the 
development of new anti-HIV molecules. 
In this study, we investigated whether a pool of 
CCR5 that is not accessible to native chemokines 
would be a target for inhibiting HIV-1 infection. 
For this purpose, we studied the molecular 
mechanisms whereby the N-terminally modified 
CCL5 analog PSC-RANTES shows improved 
antiviral activity compared to native chemokines 
(13,14). This drug protects macaques from HIV-1 
infection after vaginal application (15). The 
exceptional capacity of PSC-RANTES to inhibit 
infection is related to its ability to increase CCR5 
down-regulation (11,13). A super agonist activity 
of PSC-RANTES (16) and its ability to sequester 
CCR5 into the trans-Golgi network (17) have been 
suggested to play a role in this context. However, 
we report here that PSC-RANTES also displays 
the unique property of recognizing a larger array of 
CCR5 conformational states than native 
chemokines, making it more efficient in recruiting 
"-arrestins and down-regulating CCR5. These 
findings provide evidence for the existence of a set 
of CCR5 that are not stabilized by native 
chemokines at the cell surface and highlight the 
targeting of this spare CCR5 as an anti-HIV 
principle. 
EXPERIMENTAL PROCEDURES 
Plasmids, siRNA and chemokines – The 
previously described dominant negative mutant of 
Eps15 GFP-E#95/295 (18) was a gift from A. 
Benmerah (Institut Imagine, Paris, France). YFP 
tagged-CCR5, "$arrestin2 RLuc (!arr2-Rluc) and 
the construct encoding for GFP fusions of wild-
type !-arrestin2 (!arr2-GFP) have been described 
(19,20). The double-stranded 5’-
ACCUGCGCCUUCCGCUAUG-3’ siRNA 
sequence (Dharmacon) was used to simultaneously 
target both !arr1 and !arr2 as previously described 
(21). The !arr1/2 siRNA and a scrambled siRNA 
(control: 5’-UGGUUUACAUGUCGACUAA-3’) 
(Dharmacon) were transfected by RNAimax 
(Invitrogen) according to the manufacturer's 
instructions. The chemokines MIP-1!/CCL3 and 
RANTES/CCL5 were purchased from Peprotech 
(Tebu-bio). MIP1"/CCL4 was chemically 
synthesized by F. Baleux (Institut Pasteur, Paris, 
France). 125I-CCL3 was from PerkinElmer Life 
Sciences. The CCR5 antagonist TAK779 was 
obtained through the centre for AIDS reagents, 
NIBSC, UK, with permission of Takeda Chemical 
Industries Ltd (22). The chemokine analog 5P12 
with antagonist feature was previously described 
(23). The chemokine analog PSC-RANTES (N-"-
(n-nonanoyl)-des-Ser(1)-[L-thioprolyl(2), L 
cyclohexylglycyl(3)] RANTES(4-68)) was 
provided by the Centre for AIDS Reagents, 
NIBSC, UK. PSC-RANTES carrying a C-terminal 
biotin (PSC-RANTES-biot) was synthesized 
essentially as in (13), except that synthesis of the 
C-terminal fragment was carried out on a Boc-Gly-
PAM resin, incorporating a Lys residue with an 
Fmoc-protected epsilon amino group. At the end of 
synthesis, the side chain of this Lys residue was 
deprotected and elongated successively with 
Fmoc-aminocaproic acid and Biotin-OSu. 
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Biotinylated PSC-RANTES shows 
indistinguishable activity to non-biotinylated 
material in an R5-tropic envelope-dependent cell 
fusion assay (O.H. et al., unpublished results).  
Cell lines and primary CD4+ T lymphocytes- 
The human embryonic kidney HEK293 cells stably 
expressing FLAG-tagged CCR5 WT and CCR5-
349 mutant have been described (24). The human 
A3.01 T cell line stably expressing FLAG-tagged 
CCR5 was generated by the Amaxa nucleofector 
technology (Amaxa Biosystems) and culture of 
cells for several weeks in 1 mg/ml G418 
(Geneticin; Invitrogen). Cell clones were screened 
and sorted by flow cytometry (on a MoFlo Astrios, 
Beckman Coulter) using the M1 anti-FLAG 
(Sigma) or the anti-CCR5 2D7 (BD Pharmingen) 
monoclonal antibody. FLAG-CCR5 HEK293 cells 
stably expressing "arr2-GFP were generated by 
calcium phosphate co-precipitation and specific 
sorting. HEK293 cells were grown in Dulbecco 
modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) and 
antibiotics. T cell lines were grown in RPMI 1640 
supplemented with 10% fetal bovine serum and 
antibiotics. Human CD4+ T lymphocytes were 
purified from PBMCs of healthy blood donors 
(Etablissement Français du Sang) by Ficoll 
centrifugation (PAA) followed by 
immunomagnetic selection (Miltenyi Biotec). 
They were maintained for 2 days in RPMI 1640 
medium containing phytohemagglutinin (1 µg/mL) 
and interleukin 2 (300 IU/mL) and then in medium 
containing IL-2 before use. 
Viral production and HIV-1 virion-based fusion 
assay - HIV-1 particles containing BlaM-Vpr were 
produced by co-transfection of HEK293T cells 
with a NL4-3Ren-based plasmid expressing the 
envelope glycoprotein gp160 of the HIV-1 R5-
tropic strain Bx08 (11) and pCMV-BlaM-vpr 
encoding "-lactamase fused to the viral protein 
Vpr (25). After 48 h of culture at 37°C, the virus-
containing supernatant was centrifuged at low 
speed to remove cellular debris and then 
ultracentrifuged at 72,000 # g for 90 min at 4°C to 
sediment viral particles. The virion-enriched pellet 
was resuspended in DMEM and aliquoted for 
storage at $80°C. Following 30 min incubation 
with chemokines, 1.5 x 105 primary CD4+ T cells 
were inoculated with the BlaM-Vpr-containing 
viruses (50 ng p24 Gag) by 1 h spinoculation at 
4°C and incubated 2 h at 37°C. Cells were then 
loaded with CCF2/AM, the BlaM-Vpr substrate (2 
h at RT) and fixed. Enzymatic cleavage of 
CCF2/AM by "-lactamase (the readout of viral 
entry fusion) was measured by flow cytometry 
(FACScanto, BD) and data were analyzed with 
FlowJo software. The percentage of fusion 
corresponds to the percentage of cells displaying 
increased cleaved CCF2/AM fluorescence (447 
nm). 
Radioligand Binding Assays on A3.01-FLAG-
CCR5 cell lines - Displacement of 125I-CCL3 (0.5 
nM) in the presence of CCL5, CCL4, CCL3 or 
PSC-RANTES was performed as in (11) except 
that incubations were done in Eppendorf tubes at 
4°C. To remove unbound 125I-CCL3, cells were 
pelleted at 4 °C (5 min) and then washed once with 
washing buffer (50 mM Hepes, pH 7.4, 5 mM 
MgCl2, 1 mM CaCl2, and 150 mM NaCl). Pellets 
were resuspended in the washing buffer and 
radioactivity was counted in a Multi Crystal 
LB2111 (Berthold). Displacement of PSC-
RANTES-biot (1 nM) in the presence of CCL5, 
CCL3 or PSC-RANTES were done in eppendorf 
tubes at 4°C during 90 min. Unbound PSC-
RANTES-biot were remove by centrifugation and 
pellets were incubated 30 min with PBS/BSA 
0.2% containing streptavidin-PE (BD Bioscience). 
Cells were analyzed by flow cytometry (Gallios 
flow cytometer, Beckman Coulter).  Analysis of 
the binding data was made using the Prism 
software (GraphPad). 
[35S]GTP!S binding - [35S]GTP%S binding to 
crude membrane preparations of CCR5-expressing 
HEK293T cells was described previously (9). 
Briefly, membranes were incubated for 15 min at 
30°C in 20 mM HEPES, pH 7.4, containing 100 
mM NaCl, 10 µg/ml saponin, 1 µM GDP and 3 
mM MgCl2, in the presence or absence (basal 
[35S]GTP%S binding) of chemokines. Then, 0.1 nM 
[35S]GTP%S (PerkinElmer) was added to 
membrane-containing mixes, which were 
incubated for 30 min at 30°C. The incubation was 
stopped by centrifugation (800 x g for 10 min) at 
4°C and removal of supernatants. Microplates 
were counted 2 min per well in a PerkinElmer 
Wallac 1450 Microbeta Trilux (PerkinElmer Life 
and Analytical Sciences). 
Calcium Measurements – FLAG-CCR5 
expressing HEK293 cells or primary CD4+ T cells 
were incubated for 20 min at 37°C with 1.5 µM 
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Fura-2/AM (Molecular Probes). Calcium 
measurements by spectrofluorimetry were 
performed in mammalian saline as previously 
described (26) with a Cary Eclipse 
spectrofluorimeter (Varian) (excitation: 340 and 
380 nm; emission: 510 nm). For measurements by 
microscopy, cells were analyzed with a Nikon 
TE2000 microscope (Nikon, Melville, NY) 
equipped with a cooled CDD camera (cascade, 
princenton Instruments) and a Matafluor imaging 
system (Roper Scientific) as described (27). 
Calcium levels are represented as a ratio 340/380 
fluorescence intensity. 
Fluorescence flow cytometry assays of receptor 
internalization and recycling – Flow cytometry 
was used to quantitate the internalization and the 
recycling of CCR5 by measuring the levels of cell 
surface FLAG-tagged receptors as described 
previously (24). Mean values were used to 
compute the proportion of internalized receptors as 
indicated by a decrease of immunoreactive surface 
receptor with agonist compared to untreated cells. 
The percentage of receptor recycling was the 
proportion of receptors that was recovered at the 
cell surface out of the internalized receptors. 
Cell surface biotinylation and assay of agonist-
induced proteolysis - Western blot – The cell 
surface biotinylation assay was described 
previously (24). Briefly, cells were incubated with 
300 %g/ml sulfo-NHS-biotin (Pierce) in PBS at 
4°C for 30 minutes. Unreacted sulfo-NHS-biotin 
was quenched by washes with ice-cold Tris-
buffered saline. Cells were incubated with media at 
37°C for the indicated times in the absence or 
presence of agonists. They were chilled on ice, 
washed with PBS and extracted with lysis buffer 
(0.5% TX-100, 10 mM Tris-HCl, 120 mM NaCl, 
25 mM KCl, protease inhibitors mixture). Extracts 
were centrifuged and equal amounts of proteins 
(Bradford analysis) were incubated with 25 %l of 
streptavidin beads (Pierce) overnight (O/N). Eluted 
proteins were resolved by SDS-PAGE and 
transferred to a PVDF membrane for Western blot 
analysis. For receptors detection, blots were 
incubated with M1 anti-FLAG antibody (Sigma) 
and then with an HRP-coupled goat anti-mouse 
IgG for enzyme-linked chemiluminescence 
detection (ECL system, Amersham Life Sciences). 
A control of the quantity of proteins per lane was 
performed after an acid strip and incubation of 
blots with an avidin-HRP complexe (Sigma). Band 
intensities were quantified by densitometry of 
films. 
For detection of "-arrestin after siRNA 
transfection, equal amount of proteins were 
resolved by SDS-PAGE and transferred to a PVDF 
membrane. Blots were incubated O/N with the 
anti-"$arrestin antibody D24H9 (Cell signaling). 
After washing, blots were incubated with an anti-
rabbit-HRP antibody (Jackson) before detection by 
ECL. A control of the quantity of proteins per lane 
was performed after an acid strip and incubation of 
blots with anti-LDH5 (Biodesign) and anti-goat-
HRP (Dako) antibodies. 
siRNA rescue  – For recombinant protein re-
expression in FLAG-CCR5-349 expressing 
HEK293 cells, "arr2-GFP was mutated by site 
directed mutagenesis to ACC TGT GCC TTT 
AGG TAT G (underlined bases show synonymous 
mutations introduced) in order to assure resistance 
to knockdown by "arr1/2 siRNA (res-"arr2-GFP). 
siRNA (10 nM) and plasmid (50 ng) were co-
transfected (with 48 h interval between the two) 
using RNAimax and Lipofectamine 2000 
respectively. Experiments of internalization were 
conducted 3 days after siRNA transfection. After 
staining, GFP-positive cells were analyzed for 
CCR5 cell surface expression by flow cytometry 
(Gallios flow cytometer, Beckman Coulter). 
BRET assays - BRET assays were performed as 
described previously (28). Briefly, 24 h post-
transfection (with 30 ng "arr2-Rluc-encoding 
plasmid and increasing concentrations of plasmid 
encoding CCR5-YFP), cells were detached with 
DMEM without phenol red (Invitrogen) and 
distributed in white 96-well optiplates (Perkin 
Elmer). 50 nM of chemokines was added and 
incubated at 37°C for the indicated times. After 
incubation, Coelentherazine h (Interchim) was 
added to a final concentration of 5 µM, and 
incubated for 3 minutes at 25°C. BRET readings 
were collected using a Multilabel Reader Mithras 
LB 940 (Berthold Technologies). Substrate and 
light emissions were detected at 480 nm (Rluc) and 
540 nm (YFP) for 1 second. The BRET signal 
corresponds to the ratio between fluorescence 
emitted by YFP and the light emitted by Rluc 
(YFP/Rluc). The ratio values were corrected by 
substracting background BRET signals detected 
when "arr2-Rluc was expressed alone. mBRET 
values were calculated by multiplying these ratios 
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by 1000. For kinetics analysis, cells were 
transfected with 100 ng "arr2-Rluc and 250 ng 
CCR5-YFP. The day after, Coelenterazin h and the 
agonist were added simultaneously, and the BRET 
signal was measured over time. 
Total Internal Reflection Fluorescence (TIRF) 
microscopy – 4 x 105 FLAG-CCR5/"arr2-GFP 
expressing HEK293 cells plated on MatTek plates 
were incubated in the presence or absence of 2 nM 
CCL5 or PSC-RANTES in DMEM/1%BSA 
medium for the indicated time. Cells were put on 
ice and fixed with PFA 4% at 4°C during 40 min 
before 3 wash in PBS. Experiments were 
performed using a TIRF microscope (IX81F-3, 
Olympus) equipped with a 100XNA 1.45 Plan Apo 
TIRFM Objective (Olympus) and fully controlled 
by CellM (Olympus). Images were collected using 
an IxonEM+ Camera (DU885, Andor). All the 
TIRF images analyses were performed using ICY 
software (http://icy.bioimageanalysis.org). The 
number of spot detected per cells was normalized 
to the size of the cell surface (29). 
 
RESULTS 
Native chemokines and PSC-RANTES trigger 
similar G-protein signaling but different CCR5 
intracellular trafficking- The antiviral activity of 
PSC-RANTES (IC50= 0.38±0.14 nM), which is 
much more potent than that of CCL5 or CCL4 
(IC50= 259±26 nM and >1000 nM, respectively) 
(Fig. 1A), is attributed to its ability to induce a 
stronger CCR5 down-regulation (13). We 
investigated whether this effect could result from 
increased binding affinity of PSC-RANTES for 
CCR5 or from an increased ability to activate G-
proteins (16). Native chemokines and PSC-
RANTES displaced 125I-CCL3 binding to CCR5-
expressing A3.01 cells with comparable potencies 
(IC50= 2.6±0.11, 2±0.25, 1.1±0.14 nM and 
1.2±0.12 for CCL5, CCL4, CCL3, PSC-RANTES, 
respectively) (Fig. 1B), in line with previous 
observations (11). Of note, the extent of 125I-CCL3 
binding displacement by the unlabeled chemokines 
varied with the concentration of 125I-CCL3, 
indicating that a competitive inhibition of 125I-
CCL3 binding occurred (30) (Fig. 1B, insert). 
These chemokines also displayed similar potencies 
and efficacies for activating G-proteins in 35S-
GTP%S binding assays (EC50= 3.4±0.27 and 
7±0.17 nM for CCL5 and PSC-RANTES, 
respectively) (Fig. 1C) and for calcium responses 
(EC50= 2.3 nM for CCL5 and PSC-RANTES) (Fig. 
1D). 
Despite the similar output of CCL5 and PSC-
RANTES in terms of G-protein activation, the 
analog promoted stronger receptor sequestration 
than the native chemokine (Fig. 1, E and F), in line 
with observations on other cells (13). After 30 min 
stimulation with a saturating concentration (50 
nM) of PSC-RANTES or CCL5 (Fig. 1E), cell 
surface CCR5 was reduced by 50% and 20%, 
respectively. We investigated whether these 
differences could be explained by differences in 
the rates of CCR5 endocytosis or recycling to the 
cell surface (24). In cells expressing CCR5-349, a 
receptor mutant unable to recycle (24), PSC-
RANTES-induced internalization reached 90% at 
30 min, whereas CCL5-dependent internalization 
only reached 30% (Fig. 1F). Endocytosis half-life 
was 50 min for CCL5 and 7 min for PSC-
RANTES, indicating that PSC-RANTES induced 
faster receptor down-regulation than the native 
chemokine. CCR5 recycling after PSC-RANTES-
induced endocytosis was maintained, although at a 
slower rate compared to CCL5 (Fig. 1G). In 
addition, regardless of the agonist used, the 
receptor was not directed to the degradation 
pathway (Fig. 1, H and I), in agreement with 
previous data (17). In conclusion, both improved 
receptor endocytosis and slower recycling likely 
explain the strong CCR5 down-regulation and the 
potent antiviral activity of PSC-RANTES. 
Compared to native chemokines, PSC-RANTES 
induces increased "-arrestin2 recruitment to 
CCR5- We next investigated whether PSC-
RANTES-dependent CCR5 trafficking would 
involve a distinct endocytic pathway. Both CCL5- 
and PSC-RANTES-induced internalization were 
impaired in the presence of the #95/295 dominant 
negative mutant of Eps15 (Fig. 2A), a component 
of clathrin-coated pits (CCPs) (18). Thus both 
agonists induced CCR5 internalization via the 
clathrin-driven endocytic pathway. As a control, 
#95/295 also inhibited the internalization of 
transferrin (not shown). 
GPCR endocytosis most often requires "-
arrestins, which bridge the receptor cargo to AP2 
and clathrin (31). Silencing (70% reduction) "-
arrestin1 and 2 ("arr1 and "arr2) endogenous 
expressions with siRNA similarly decreased 
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CCR5-349 internalization regardless of the agonist 
used (Fig. 2, B-D). To test specificity, we rescued 
CCR5 internalization by co-transfecting a "arr2-
GFP mutant resistant to knockdown by "arr1/2 
siRNA (Fig. 2E). These experiments indicates that 
"-arrestins contributed to CCR5 internalization 
whatever the agonist. These results are consistent 
with recent data showing intracellular clustering of 
"arr2 after CCR5 stimulation with PSC-RANTES 
(32). 
We examined whether the improved CCR5 
sequestration and slow recycling induced by PSC-
RANTES were due to increased affinity of "arr2 
for the PSC-RANTES-occupied receptor. "arr2 
translocation to agonist-bound GPCRs can be 
monitored using Bioluminescence Resonance 
Energy Transfer (BRET) (28). We conducted 
BRET saturation assays in living HEK293 cells 
co-expressing plasmids encoding "arr2-Rluc as the 
BRET donor, and CCR5-YFP as the BRET 
acceptor, in the presence or absence of 50 nM 
PSC-RANTES or CCL5. We obtained hyperbolic 
saturation curves in the presence of both agonists, 
indicating a specific recruitment of "arr2 to 
agonist-bound CCR5 (Fig. 3A). BRET50 values 
(YFP/Rluc value for half-maximal BRET), which 
reflect the propensity of "arr2-Rluc to associate 
with CCR5-YFP, were not significantly different 
after CCL5 and PSC-RANTES stimulation 
(0.58±0.27 vs 0.22±0.05; p=0.24 in unpaired two-
tailed student t test), ruling out the hypothesis of an 
increased affinity of "arr2 for PSC-RANTES-
occupied receptors, compared to CCL5-occupied 
receptors. Accordingly, kinetic analysis revealed 
similar half-time values for the association of 
"arr2 to CCL5- and PSC-RANTES-bound CCR5 
(16.2±2.7 vs 11.2±2.7 min; p=0.1 in unpaired two-
tailed student t test) (Fig. 3B).  
These data suggest that PSC-RANTES and 
CCL5 stabilize CCR5 in a similar "arr2-interacting 
conformation. In this context, the 3-fold increase 
of the BRETmax values (the BRET values 
corresponding to the plateau of the hyperbola) in 
the presence of PSC-RANTES might indicate that 
a larger fraction of "arr2 (the BRET donor) would 
be associated with CCR5 (the acceptor) in the 
presence of PSC-RANTES compared to CCL5 
(Fig. 3A). However, since BRETmax values also 
depend on the distance and on the relative 
orientation of the BRET donor and acceptor (28), 
different BRETmax values could also correspond to 
different conformations of "arr2/CCR5 complexes 
elicited by CCL5 and PSC-RANTES. To 
discriminate between these two possibilities, we 
examined the amount of "arr2 recruited at the 
plasma membrane using Total Internal Reflection 
Fluorescence (TIRF) microscopy, which restricts 
the observation to the first 100–200 nm from the 
coverslip (33). TIRF acquisitions were performed 
in fixed cells stably expressing "arr2-GFP and 
FLAG-CCR5 (Fig. 3, C and D). "arr2-GFP 
fluorescence was not enriched at the plasma 
membrane in untreated cells (Fig. 3C). After 
receptor stimulation with PSC-RANTES or 
CCL5, "arr2-GFP was recruited into spots close to 
the plasma membrane, likely corresponding to 
CCR5-containing CCPs (Fig. 3C). The number of 
spots increased over time after agonist exposure: at 
all time points the number of "arr2-GFP spots in 
PSC-RANTES-treated cells was at least three 
times higher than in CCL5-treated cells (Fig. 3D). 
Note that the surface of spots was not significantly 
different between both treatments at 10 min 
(surfaceCCL5=5±0.8 pixels; surfacePSC-RANTES= 
6.25±0.6 pixels) and slightly increased for PSC-
RANTES-treated cells at 15 min 
(surfaceCCL5=4.7±0.6 pixels; surfacePSC-RANTES= 
7.5±0.6 pixels). This indicates that the difference 
in the amount of "arr2-GFP spots detected after 
PSC-RANTES treatment compared to CCL5 is 
mainly due to an increase in the quantity of "arr2 
recruited to the plasma membrane rather than to a 
difference in the size distribution of "arr2-GFP. 
These results indicate that PSC-RANTES may 
trigger the formation of a larger number of "arr2-
CCR5 complexes compared to CCL5. This may 
explain why after stimulation with CCL5 only a 
fraction of "arr2-Rluc molecules interacted with 
CCR5-YFP in saturation BRET experiments (see 
Fig. 3A). The increased recruitment of "arr2 to 
CCR5 after PSC-RANTES exposure likely 
contributed to the increased internalization of 
CCR5 (Fig. 1), compared to that observed after 
CCL5 stimulation.  
PSC-RANTES stabilizes a pool of CCR5 that is 
not accessible to native chemokines- The data 
above are consistent with a model where PSC-
RANTES can activate a larger pool of CCR5 than 
native chemokines. To explore the hypothesis that 
some CCR5 conformations would bind PSC-
 7 
RANTES but not native chemokines, we 
conducted competition experiments, in which 
increasing concentrations of unlabeled chemokines 
(CCL5, CCL3, PSC-RANTES) were used to 
inhibit the binding of biotinylated PSC-RANTES 
(PSC-RANTES-biot) to CCR5 (Fig. 4A). Whereas 
PSC-RANTES competed with PSC-RANTES-biot 
for binding to the receptor (IC50 = 7±0.67 nM), 
native chemokines, even at micromolar 
concentration could not (Fig. 4A). This result, 
showing that PSC-RANTES-biot prevents the 
binding of native chemokines to CCR5, contrasts 
with the competitive inhibition of 125I-CCL3 
binding by unlabeled chemokines shown Fig. 1B, 
and suggests that the receptors binding PSC-
RANTES-biot and those binding 125I-CCL3 
represent two different receptor populations. We 
measured a slow dissociation rate of PSC-
RANTES-biot from CCR5 (Fig. 4B), which could 
contribute to this result. Alternatively, but not 
exclusively, native chemokines might display 
marginal affinity for this particular fraction of 
CCR5, thereby explaining why they failed to 
displace PSC-RANTES-biot. Considered 
altogether, the results from Fig. 1B and 4A suggest 
that CCR5 exist in two distinct pools, one with 
high affinity for both PSC-RANTES and native 
chemokines, and another, the larger one, with high 
affinity for PSC-RANTES and minimal affinity for 
native chemokines. 
If PSC-RANTES might stabilize an additional 
pool of CCR5, a significant fraction of receptors 
internalized in response to PSC-RANTES would 
not be accessible to native chemokines. This would 
explain why PSC-RANTES induces a stronger 
CCR5 down-regulation than native chemokines. 
To investigate this possibility, we tested both in 
HEK293 cells (Fig. 4C) and in A3.01 T cell line 
(Fig. 4D) whether a saturating concentration of 
native chemokines could prevent subsequent PSC-
RANTES-induced internalization. Pre-incubating 
cells 90 min at 4°C with 100 nM CCL5 (or 300 
nM CCL4) neither influenced the potency nor 
efficacy of PSC-RANTES to induce CCR5 
internalization (Fig. 4, C and D), demonstrating 
that PSC-RANTES can induce the internalization 
of receptors that are not targeted by native 
chemokines. 
The binding of PSC-RANTES to a pool of 
spare receptors was also supported by experiments 
of agonist-induced CCR5 desensitization. A first 
stimulation with CCL5 [C] promoted a CCR5-
dependent calcium release, whereas a second 
challenge with the same chemokine failed to 
induce any further response (Fig. 4, E and F - [CC] 
on graphs). In contrast, a second challenge by 
PSC-RANTES [P] could elicit a calcium response 
(Fig. 4, E and F-[CP]), suggesting that a 
proportion of CCR5, not desensitized by the first 
stimulation with CCL5, could still be activated by 
PSC-RANTES. In a parallel experiment, the initial 
stimulation by PSC-RANTES desensitized all 
receptors, since no further calcium signal could be 
elicited by challenge with PSC-RANTES or the 
native chemokine (Fig. 4, E and F-[PP; PC]). 
These data were obtained both at a single cell level 
(Fig. 4E) and in assays on cell populations (Fig. 
4F). These results were confirmed in primary 
CD4+ T cells (Fig. 4G). 
DISCUSSION 
In this study, we investigated whether a pool of 
CCR5 that is not occupied by native chemokines 
could represent a target for inhibiting HIV-1 
infection. Our results are consistent with the 
existence of spare forms of CCR5 on the cell 
surface, which bind PSC-RANTES with high-
affinity but not native chemokines. These results 
support the concept that CCR5 exists in multiple 
conformations that are differentially stabilized by 
functionally different ligands. They are also 
relevant in light of our recent findings showing 
that HIV-1 can escape inhibition by native 
chemokines by exploiting low-chemokine affinity 
conformations of CCR5 (11). PSC-RANTES 
would bypass this limitation by targeting spare 
CCR5. This would lead to a larger number of 
"arr2/CCR5 complexes, stronger CCR5 down-
regulation and potent HIV-1 inhibition compared 
to native chemokines. 
Spare CCR5 receptors. GPCRs are dynamic 
proteins adopting an array of inactive and active 
conformations (6,7). Recent NMR experiments 
suggest that agonists turn the receptor into 
heterogeneous ligand-bound intermediate states, 
which are stabilized into fully active 
conformations once bound to downstream 
effectors (6). In this context, our BRET 
experiments (showing similar affinity of "arr2 for 
CCL5-bound and PSC-RANTES-bound CCR5) 
suggest that PSC-RANTES and native chemokines 
stabilize CCR5 into a similar intermediate 
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conformational state likely to interact with "arr2. 
Consequently, the higher amount of "arr2/CCR5 
complexes formed by PSC-RANTES could result 
from a higher affinity of PSC-RANTES with this 
intermediate conformation compared to native 
chemokines. Alternatively, the higher amount of 
"arr2/CCR5 complexes could depend on the 
selection by PSC-RANTES of additional resting 
receptor states. Consistent with these two 
hypotheses, we found that native chemokines 
failed to prevent biotinylated PSC-RANTES 
binding to CCR5 (Fig. 4A), while they were as 
potent as unlabeled PSC-RANTES in displacing 
125I-CCL3 binding (Fig. 1B). This suggests that 
CCR5 may exist in at least two different 
conformational states, one with high-affinity for 
both PSC-RANTES and native chemokines, and 
the other, the larger one, binding preferentially the 
analog. We previously showed that CCR5 
coupling to nucleotide-free forms of G-proteins 
(NFG-proteins) is necessary for high-affinity 
binding of native chemokines (11). It is thus 
possible that the pool of CCR5 that binds PSC-
RANTES but not native chemokines corresponds 
to NFG-protein-uncoupled receptors, whereas the 
pool of CCR5 capable of binding both native 
chemokines and PSC-RANTES would correspond 
to NFG-protein-coupled receptors. In agreement 
with previous experiments showing that the 
recruitment of "arr2 to CCR5 and CCR5 
endocytosis are independent of G-proteins (9,11), 
G-protein-uncoupled and PSC-RANTES-bound 
CCR5 would maintain the capacity of recruiting "-
arrestins. 
The above results imply that in the range of 
concentrations at which native chemokines and 
PSC-RANTES produced comparable effects on G-
protein activation (Fig. 1), native chemokines 
occupy a smaller fraction of receptors than PSC-
RANTES. In other words, this indicates that not all 
CCR5 are occupied by native chemokines to 
produce full G-protein activation. Such a property 
of an agonist is also observed in other receptor 
systems (34), where reserve receptors (also named 
spare receptors) exist and are not needed for 
agonists to evoke a maximal functional response. 
Here, we provide evidence indicating that a 
population of CCR5 is poorly accessible to native 
chemokines, while being targeted by PSC-
RANTES, supporting the concept of spare CCR5. 
First, we observed that saturating concentrations of 
native chemokines failed to prevent "-arrestin-
dependent, PSC-RANTES-mediated CCR5 
internalization (Fig. 4, C and D). Second, while 
PSC-RANTES fully desensitized further CCR5 
activation mediated by native chemokines, the 
reverse situation was not observed (Fig. 4, E-G). 
This latter observation also suggests that a fraction 
of spare receptors, which are targeted by PSC-
RANTES, would represent receptors capable of 
interacting with G-proteins. This result might 
appear at odds with the observation that PSC-
RANTES and native chemokines activate G-
protein dependent signals with comparable 
efficacy (Fig. 1). However, PSC-RANTES might 
stabilize intermediate CCR5 conformations likely 
to couple to G-proteins less efficiently than those 
induced by native chemokines. This suggests that 
PSC-RANTES-occupied CCR5 displays a bias 
toward "-arrestin recruitment over G-protein 
coupling compared to native chemokines. This 
hypothesis is in line with recent data showing that 
biased agonism, which results in differential 
activation of different signaling pathways, is a 
common property of chemokines (35). 
Molecular determinants and mechanisms 
featuring PSC-RANTES functionality. The 
classical model for chemokine binding to CCR5 
and receptor activation proposes that the 
chemokine core binds extracellular regions of the 
receptor while the N-terminal tail of the 
chemokine interacts with the transmembrane 
domains (36). The length and the amino-acid 
composition of the N-terminal tail of CCR5-
binding chemokines affect their binding and 
signaling properties as well as their anti-HIV 
potency (37,38). Moreover, different classes of N-
terminal-modified CCL5 analogs displaying 
improved anti-HIV properties have different 
pharmacological profiles (23), suggesting that they 
may stabilize different conformations of CCR5. 
Mutations in CCR5 transmembrane domains 
differentially impact the antiviral activities of these 
chemokine analogs including PSC-RANTES (39). 
Interestingly, these mutations did not alter the 
ability of the analogs to displace 125I-CCL3 
binding to the receptor (39). We can hypothesize 
that the mutations may change the relative 
proportions of receptors likely to establish high-
affinity interactions with the analogs. In line with 
this hypothesis, recent computational docking 
approaches showed that mutations in the 
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transmembrane domains stabilize different sets of 
CCR5 conformations, each of which differs in 
their ability to bind different ligands and/or 
different effectors (40). 
Overall, our results are consistent with the view 
that the robust CCR5 down-regulation following 
PSC-RANTES stimulation results from the 
stabilization by the N-terminal tail of PSC-
RANTES of a higher amount of "arr2/CCR5 
complexes but not from faster CCR5 
internalization. Indeed, we observed similar 
kinetics of CCR5 internalization (Fig. 1E) and of 
"arr2 recruitment (Fig. 3B) regardless of the 
agonist used, in agreement with previous studies 
(11,17). We also showed different rates of CCR5 
recycling after PSC-RANTES- and CCL5-induced 
endocytosis (Fig. 1G) (17). While the strength of 
"arr2/receptors interactions appears to control the 
extent of receptor recycling and the post-endocytic 
fate of receptors (41), our results showing similar 
"arr2 affinities for PSC-RANTES-bound and 
CCL5-bound CCR5 (Fig. 3A) do not support this 
hypothesis in the case of CCR5.   
In contrast to wild-type (WT) CCR5, results on 
the recycling-defective mutant CCR5-349 show 
different rates of internalization depending on 
PSC-RANTES or CCL5 (Fig. 1F). CCL5 caused a 
slower rate of CCR5 internalization compared to 
PSC-RANTES. Note that all of the CCR5-349 will 
finally be removed from the cell surface, which is 
not the case of WT receptor, where a plateau was 
observed. This suggests that CCR5-349 
internalization involves both high-chemokine 
affinity receptors and spare receptors (that are of 
high-affinity for PSC-RANTES but bind poorly 
native chemokines). In this context, the low 
affinity of CCL5 for spare CCR5-349 and/or a 
slow isomerization rate between low-CCL5 
affinity and high-CCL5 affinity conformations of 
CCR5-349 may explain why the native chemokine 
induces a slower receptor internalization compared 
to PSC-RANTES. Conversely, similar kinetics of 
internalization of WT CCR5 by PSC-RANTES 
and CCL5 suggest that both ligands engage the 
same high-affinity population of WT CCR5. 
Role of spare receptors in HIV-1 infection and 
inhibition. The observation that chemokines 
display high-affinity binding to CCR5 and anti-
HIV-1 activity in vitro led to the proposal that they 
act as a natural barrier against HIV-1 in vivo, but 
their role in HIV-1 transmission and progression of 
infection remains debated (42). CCR5 chemokines 
show antiviral potencies lower than would be 
expected based on their CCR5 binding affinity 
constants, indicating that HIV-1 could escape 
inhibition by chemokines (16,38,43). The 
existence of a set of CCR5, which are poorly 
accessible to chemokines, but could be exploited 
by HIV-1, might contribute to the low efficiency 
of CCR5 chemokines as a HIV-1 barrier and 
constitute a viral escape route. We previously 
demonstrated that different cell surface 
conformations of CCR5, which depend on whether 
the receptor interacts or not with heterotrimeric G-
proteins, are differentially used by native CCR5 
chemokines and HIV envelope glycoproteins (11). 
In particular, we revealed that G-protein uncoupled 
CCR5 represent low-chemokine affinity receptors, 
while constituting a portal for HIV-1 entry. Our 
current findings show that the pool of CCR5 with 
high-chemokine affinity probably represents only a 
minor fraction of the total receptor pool. This is in 
agreement with the small amount of nucleotide 
free forms of G-proteins present in a cell, which 
confer to the receptor a high-affinity for agonists 
(44).  
Finally, our results are consistent with the fact 
that targeting spare receptors allows PSC-
RANTES to form an increased amount of 
"arr2/CCR5 complexes, leading to a stronger 
down-regulation of CCR5 and potent HIV entry 
inhibition. Thus spare CCR5 might represent a 
pool of co-receptors capable of supporting HIV-1 
entry. This is in line with previous studies showing 
that HIV-1 entry is a cooperative process that 
requires the recruitment of several CD4 and co-
receptor molecules into a fusion complex (45). In 
this context, HIV-1 could use these spare receptors 
in addition to high-chemokine affinity receptors to 
enter into host cells more efficiently. Furthermore, 
targeting spare receptors would allow PSC-
RANTES to bypass CCR5 populations with higher 
affinity for the viral envelope glycoprotein (11). 
The example of PSC-RANTES thus illustrates a 
new principle to inhibit HIV-1 infection and 
provides a basis for future strategies on the 
development of new inhibitors. 
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Figure legends 
 
Figure 1: Functional properties of PSC-RANTES and native chemokines. A, Chemokine-mediated 
inhibition of fusion between Bx08Ren viruses containing BlaM-Vpr and CCF2-AM-loaded primary CD4+ 
T lymphocytes. B, Displacement of 0.5 nM 125I-CCL3 binding to CCR5-expressing A3.01 cells by 
increasing concentrations of the indicated unlabeled chemokines. Insert -Displacement of increasing 
concentrations of 125I-CCL3 binding to CCR5-expressing A3.01 cells by 1.5 nM CCL3 or PSC-RANTES. 
C, Chemokine-induced 35S-GTP%S binding to CCR5-expressing HEK293T cell membranes. D, Calcium 
responses elicited in CCR5 Fura2-loaded HEK293 cells by indicated chemokines and measured by 
spectrofluorimetry (ratio: F340/F380). In panels A to D, data (mean±s.e.m of 2 or 3 independent 
experiments) were fitted according to a sigmoidal dose-response model with a variable slope. E and F, 
CCR5 internalization. Cell surface expression of FLAG-CCR5 (E) or FLAG-CCR5-349 (F) was 
monitored by flow cytometry in stable HEK293 cell clones after 50 nM chemokine stimulation for the 
indicated time. Percentage of total bound antibody was calculated from mean fluorescence intensity 
relative to untreated cells (mean±s.e.m from at least 2 independent experiments). G, CCR5 recycling. 
FLAG-CCR5 expressing HEK293 cells fed with anti-FLAG antibody were treated with 200 nM CCL5 or 
10 nM PSC-RANTES to obtain 40% of CCR5 internalization for both agonists. Receptor recovery at the 
cell surface, in the presence of an excess of TAK779, was monitored by flow cytometry (mean±s.e.m, 
n=3). Panels E to G, *p<0.05; **p<0.01 compared to CCL5-treated cells in unpaired two-tailed student t 
test. H, Post-endocytic sorting of CCR5. Biotin degradation assay of FLAG-CCR5 in cells treated with 
CCL5 (100 nM) or PSC-RANTES (10 nM) for 1, 2 or 4 hours. Representative anti-FLAG blots out of 6 
are shown. I, Quantification of blots from experiments performed in (H). The amount of cell surface 
receptors was quantified by densitometry and plotted relative to the amount of receptor detected in 
untreated cells (mean±s.e.m, n=6). The amounts of cell surface receptors were not statistically different 
(p=0.39 in unpaired two-tailed student t test) in the presence of CCL5 or PSC-RANTES. 
 
Figure 2: PSC-RANTES internalization follows a clathrin- and "-arrestin-dependent pathway. 
A, Eps15 dominant negative mutant GFP-#95/295 inhibits CCR5 internalization. Cell surface expression 
of CCR5 in GFP-#95/295- or GFP- (control) transfected HEK293 cells was monitored after 30 min of 50 
nM chemokine stimulation. GFP positive cells were analyzed by flow cytometry (mean±s.d of 2 
independent experiments). B-D, "$arrestins1/2 are involved in CCR5 internalization. B, Western blot of 
total cellular levels of "arr1/2 in CCR5-349-expressing HEK293 cells transfected (72 h) with either 
nonsilencing siRNA (siCTL) or "arr1/2 siRNA (si"arr) (10 nM). Lysates were also blotted for LDH5 to 
test the specificity of knockdown. Representative blots out of 3 independent experiments are shown (NT, 
non transfected cells). C and D, Cell surface expression of CCR5-349 was monitored by flow cytometry 
after stimulation with 100 nM CCL5 (C) or PSC-RANTES (D) of siRNA treated cells for the indicated 
time. E, Rescue of siRNA-mediated "-arrestin knockdown. CCR5-349-expressing HEK293 cells were co-
transfected, or not (no plasmid), with "arr1/2 siRNA (10 nM) and a plasmid encoding GFP (50 ng) or a 
siRNA-resistant "arr2-GFP construct (res-"arr2-GFP) (50 ng) and stimulated 20 min with 100 nM PSC-
RANTES (n=4). *p <0.05, **p <0.01 compared to siRNA control in unpaired two-tailed student t test. 
 
Figure 3: PSC-RANTES triggers a massive recruitment of "-arrestin2 to CCR5. A, Saturation 
BRET experiments in cells expressing "arr2-Rluc and increasing amounts of CCR5-YFP in basal 
conditions (untreated) or after 10 min chemokine (50 nM) stimulation (fitted according to a one site 
binding model, 4 independent experiments). B, Kinetics of BRET after chemokine  (50 nM) stimulation 
(fitted according to a one phase association model). Values correspond to the mean±s.e.m of 4 
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independent experiments. C and D, TIRF microscopy on HEK293 cells stably expressing "arr2-GFP and 
FLAG-CCR5 obtained 5, 10 and 15 min after stimulation with 2 nM CCL5 or PSC-RANTES. C, "arr2 
spots were detected on TIRF images. Scale bar: 5µm. D, Quantification of the spots over time using the 
ICY software (mean±s.d; n!10 cells). **p<0.01, ***p<0.001 compared to CCL5-treated cells in unpaired 
two-tailed student t test. 
 
Figure 4: PSC-RANTES stabilizes spare CCR5 conformations. A, Displacement of 1 nM PSC-
RANTES-biot binding to CCR5-expressing A3.01 cells by increasing concentrations of the indicated 
chemokines. Data with unlabeled PSC-RANTES used as competitor were fitted according to one site 
competitive binding model (mean±s.e.m, n=4). B, PSC-RANTES-biot or 125I-CCL3 dissociation from 
CCR5. CCR5-expressing A3.01 cells were incubated 90 min with 1 nM PSC-RANTES-biot or 120 min 
with 0.5 nM 125I-CCL3. Dissociation was initiated by addition of 100 nM of the high-affinity CCR5 
antagonist 5P12. PSC-RANTES-biot or 125I-CCL3 remaining bound to CCR5 was measured over time and 
analyzed as in Fig. 4A and 1B (one representative experiment out of 2). C and D, Dose-dependent CCR5 
internalization in CCR5-349-expressing HEK293 cells (C) or in CCR5-expresssing A3.01 cells (D) 
mediated by 20 min (C) or 5 min (D) stimulation with PSC-RANTES at 37°C. C, Receptor internalization 
was measured after incubation, or not, of CCR5-349-expressing HEK293 cells with 100 nM CCL5 at 4°C 
for 90 min (data were fitted according to a sigmoidal dose-response model with a variable slope) 
(mean±s.e.m, n=4). D, Receptor internalization was measured after incubation, or not, of A3.01 cells with 
300 nM CCL4 at 4°C for 90 min (data were fitted according to a sigmoidal dose-response model with a 
variable slope) (mean±s.e.m, n=3). E-G, Calcium responses measured in Fura2-loaded CCR5-expressing 
HEK293 cells (E and F) or primary T cells (G) stimulated twice (2 min intervals between the first and the 
second stimulation) with 15 nM chemokines. E, Results were obtained by imaging on cells coated on a 
glass coverslip. Each trace is the mean of at least 25 single-cell calcium responses. F and G, Results were 
obtained by spectrofluorimetry on the entire resuspended HEK293 cell population (F) (n=3 independent 
experiments) or primary T cell population (G) (one representative experiment out of 2 performed on 2 
different donors). *p<0.05, **p<0.01, ***p<0.001 in unpaired two-tailed student t test. (C: CCL5, P: PSC-
RANTES). 




